Answers are grounded in this paper and cite their sources.
Advancements in the treatment of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) (AYA-ALL) have resulted in significant survival improvements over the last decade, however AYA patients continue to face worse outcomes compared to the pediatric population. Tailoring treatments to address these differences, alongside refining supportive care and psychosocial interventions, is essential to improving the prognosis and quality of life for this unique patient population. Here we review the multiple challenges faced when treating AYA-ALL including disease biology, treatment optimization, psychosocial issues and behavioral and life stressors.
No takes yet. Share an insight, caveat, or question.
Burkart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: